

NIHR Performance in Delivery; Quarter 4; 2016/17

Id	Research Ethics Committee Ref Number	Integrated Research Application System Number	Name of Trial	Target Number of Patients Agreed?	Minimum number agreed	Maximum Number Agreed	Target Date to Recruit Patients Agreed?	Date Agreed to Recruit Target Number of Patients	Total Number of Patients Recruited at agreed Target date	Date that the trial closed to recruitment	Total number of study participants recruited	Reason for Closure of Trial	Comments
15119	13/NW/0463	124757	LP0041-63Risk of SCC on skin treated with Ingenol Mebutate or Imiquimod Cream	number agreed	7	7	date agreed	01/11/2015	6	30/04/2016	8	recruitment finished	
15121	15/YH/0428	188418	DUAL VIII: A 104-week, multi-centre, multinational, open-label, two-arm parallel, randomised to insulin degludec/liraglutide (IDegLira) vs.insulin glargine therapy in subjects with T2DM	number agreed	8	8	date agreed	22/08/2016	7	17/08/2016	7	recruitment finished	8th patient lined up for screening within original timeframe but screening closed early. Not permitted to enter screening by sponsor.
15171	15/NW/0697	183760	REACH (LPS13931): A twenty-six week, randomized, open-label, 2-arm parallel group real world pragmatic trial to assess the clinical and health outcomes benefit of Toujeo® compared to standard of care insulin for initiating basal insulin in insulin naive patients with uncontrolled type 2 diabetes mellitus, with 6 month extension.	number agreed	6	6	date agreed	27/09/2016	5	27/09/2016	5	recruitment finished	Issues with pharmacy set up delayed start of recruitment.
15172	15/NW/0698	183781	REGAIN (LPS14060): A randomized, open-label, 2-arm parallel group real world pragmatic trial to assess the clinical and health outcomes benefit of transition to Toujeor in basal insulin treated patients with uncontrolled type 2 diabetes mellitus	number agreed	6	6	date agreed	27/09/2016	2	27/09/2016	2	recruitment finished	Issues with pharmacy set up delayed start of recruitment
15173	16/LO/0340	197371	MS AURIEL : A randomized, double-blind, confirmatory trial to evaluate the efficacy, safety and immunogenicity of MSB11022 compared with European Union-Approved Humira in subjects with moderate to severe chronic plaque psoriasis.	number agreed	2	2	date agreed	31/07/2016	1	15/06/2016	1	recruitment finished	
15209	15/SC/0443	173722	OPTIMISE: CAIN457A3302 Long term clear skin maintenance treatment optimization in patients with moderate to severe chronic plaque psoriasis	number agreed	5	5	date agreed	31/01/2016	6	28/02/2016	6	recruitment finished	
17188	14/NW/0006	140059	MCRN2696 (LEO 80185 gel in adolescent psoriasis)	number agreed	2	2	date agreed	30/03/2016	2	07/09/2016	2	recruitment finished	
18651	07/S0703/57	n/a	FOXTROT: Fluoropyrimidine, oxaliplatin and targeted receptor pre-operative therapy: a controlled trial in high-risk operable colon cancer	Not Available / Not Agreed	n/a	n/a	date agreed	22/10/2014	19	22/12/2016	23	recruitment finished	Once original PI had left Trust no enthusiastic clinician at MDT to promote the study.
19780	16/LO/1384	211114	ALLURE: A multicenter, randomized, double-blind, placebo-controlled, 52-weeks study to demonstrate the efficacy, safety and tolerability of subcutaneous secukinumAb injections with 2 mL pre-filled syringes (300 mg) in adult subjects with moderate to severe plaque psoriasis	number agreed	2	2	date agreed	20/04/2017	2	11/04/2017	2	Recruitment finished	Because of problems with the drug supply the target was reduced from 5 to 2 participants